KYTO TECHNOLOGY & LIFE SCIENCE, INC.
KYTO TECHNOLOGY & LIFE SCIENCE, INC. (KBPH): 2 pipeline candidates · ~1 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.3 months
D/E 0.01 · 77% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for KYTO TECHNOLOGY & LIFE SCIENCE, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$608K
Quarterly Burn
$1.4M
Runway
1.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in KYTO TECHNOLOGY & LIFE SCIENCE, INC.'s pipeline?
KYTO TECHNOLOGY & LIFE SCIENCE, INC. (KBPH) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is KYTO TECHNOLOGY & LIFE SCIENCE, INC.'s lead drug candidate?
KYTO TECHNOLOGY & LIFE SCIENCE, INC.'s most advanced tracked candidate is xcopri (Phase 1) for Partial Epilepsy.
What is KYTO TECHNOLOGY & LIFE SCIENCE, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, KYTO TECHNOLOGY & LIFE SCIENCE, INC. has approximately 1.3 months of cash runway.
Who is the CEO of KYTO TECHNOLOGY & LIFE SCIENCE, INC.?
Los Altos is the chief executive officer of KYTO TECHNOLOGY & LIFE SCIENCE, INC. (KBPH).
Get the full picture on KYTO TECHNOLOGY & LIFE SCIENCE, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.